Please assess the completion status of the following clinical trial:

Trial Title: Polycystic Liver Disease in Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (\> 18 years old) with stage IV or V chronic kidney due to ADPKD~* Primary kidney transplant~* Living or deceased donor kidney transplant~* Estimate total liver volume of 2.5 to 7.5 L~* In addition, at the discretion of the principal investigator(s), certain subjects with numerous liver cysts but with liver volume \< 2.5 liters may be enrolled.~Exclusion Criteria:~* Pediatric patients (\< 18 years of age)~* Patients with Body Mass Index (BMI) greater than or equal to 40 kg/m\^2~* Multi-organ transplant (kidney-liver, etc.)~* When people who have one blood type receive blood from someone with a different blood type, it may cause their immune system to react. This is called (ABO) incompatibility. ABO-incompatible or positive cross-match recipients~* Patients with severe hyperlipidemia (serum cholesterol \> 350 mg/dl or serum triglycerides \> 500 mg/dl)~* Patients with leukopenia (WBC \< 3000 10/ml)~* Patients unwilling to return to the transplant center for late follow-up visits~* Patients who are currently pregnant or breast-feeding or who expect to be pregnant during the study period~* Female patients of child bearing potential and men with sexual partners of child bearing potential who do not agree to use a medically accepted method of contraception during the study period~* Patients who are not eligible for Thymoglobulin induction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Tacrolimus, mycophenolate mofetil, and prednisone
- Sirolimus Group (Type: ACTIVE_COMPARATOR): Sirolimus, mycophenolate mofetil, and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).